- $849.35m
- $728.21m
- 41
- 14
- 48
- 27
Annual balance sheet for Cassava Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 23.1 | 93.5 | 233 | 201 | 121 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 0.962 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 23.3 | 94 | 244 | 211 | 130 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.137 | 0.306 | 20.8 | 23 | 21.9 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 23.5 | 94.3 | 267 | 235 | 152 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.39 | 1.86 | 12.5 | 7.06 | 14.2 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.39 | 2.1 | 12.9 | 7.29 | 14.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 22.1 | 92.2 | 254 | 228 | 137 |
| Total Liabilities & Shareholders' Equity | 23.5 | 94.3 | 267 | 235 | 152 |
| Total Common Shares Outstanding |